Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2016-05, Vol.34 (15), p.e141-e144 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e144 |
|---|---|
| container_issue | 15 |
| container_start_page | e141 |
| container_title | Journal of clinical oncology |
| container_volume | 34 |
| creator | Falchook, Gerald S Ordóñez, Nelson G Bastida, Christel C Stephens, Philip J Miller, Vincent A Gaido, Lindsay Jackson, Tiffiny Karp, Daniel D |
| description | |
| doi_str_mv | 10.1200/JCO.2013.50.5016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1789032460</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1789032460</sourcerecordid><originalsourceid>FETCH-LOGICAL-c299t-cf177443b46e2d985a5a7db919952ce9dda9dc7bcf04f41a2c262c31596886633</originalsourceid><addsrcrecordid>eNo9kF1LwzAUhoMobk7vvZJcetOZjyZpLqVMnUw3dH7chTRNXaRLtUkF_72dm8KBA4fnfTk8AJxiNMYEoYvbfD4mCNMxQ_1gvgeGmBGRCMHYPhgiQUmCM_o6AEchvCOE04yyQzAgjHLOJR6CdlJV1kTYVDCuLHyYLOHUr1zhYtPCZ-1LG7V3BXQearjQ0Vkf4YuLq1_0qguu8cmiCS66LwvvejrEnjLwvr8_rnVdJ7mtazjr_BvMtTe2PQYHla6DPdntEXi6mizzm2Q2v57ml7PEECljYiosRJrSIuWWlDJjmmlRFhJLyYixsiy1LI0oTIXSKsWaGMKJoZhJnmWcUzoC59vej7b57GyIau2C6Z_R3jZdUFhkElGSctSjaIuatgmhtZX6aN1at98KI7UxrXrTamNaMaQ2pvvI2a69K9a2_A_8qaU_MGF4QQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1789032460</pqid></control><display><type>article</type><title>Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer</title><source>MEDLINE</source><source>American Society of Clinical Oncology Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Falchook, Gerald S ; Ordóñez, Nelson G ; Bastida, Christel C ; Stephens, Philip J ; Miller, Vincent A ; Gaido, Lindsay ; Jackson, Tiffiny ; Karp, Daniel D</creator><creatorcontrib>Falchook, Gerald S ; Ordóñez, Nelson G ; Bastida, Christel C ; Stephens, Philip J ; Miller, Vincent A ; Gaido, Lindsay ; Jackson, Tiffiny ; Karp, Daniel D</creatorcontrib><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2013.50.5016</identifier><identifier>PMID: 25366691</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - metabolism ; Carcinoma, Non-Small-Cell Lung - pathology ; Cytoskeletal Proteins - antagonists & inhibitors ; Cytoskeletal Proteins - metabolism ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Neoplasm Metastasis ; Oncogene Proteins, Fusion - antagonists & inhibitors ; Oncogene Proteins, Fusion - metabolism ; Piperidines - therapeutic use ; Proto-Oncogene Proteins c-ret - antagonists & inhibitors ; Proto-Oncogene Proteins c-ret - metabolism ; Quinazolines - therapeutic use ; Treatment Outcome</subject><ispartof>Journal of clinical oncology, 2016-05, Vol.34 (15), p.e141-e144</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c299t-cf177443b46e2d985a5a7db919952ce9dda9dc7bcf04f41a2c262c31596886633</citedby><cites>FETCH-LOGICAL-c299t-cf177443b46e2d985a5a7db919952ce9dda9dc7bcf04f41a2c262c31596886633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3729,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25366691$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Falchook, Gerald S</creatorcontrib><creatorcontrib>Ordóñez, Nelson G</creatorcontrib><creatorcontrib>Bastida, Christel C</creatorcontrib><creatorcontrib>Stephens, Philip J</creatorcontrib><creatorcontrib>Miller, Vincent A</creatorcontrib><creatorcontrib>Gaido, Lindsay</creatorcontrib><creatorcontrib>Jackson, Tiffiny</creatorcontrib><creatorcontrib>Karp, Daniel D</creatorcontrib><title>Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><subject>Adult</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Cytoskeletal Proteins - antagonists & inhibitors</subject><subject>Cytoskeletal Proteins - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - pathology</subject><subject>Neoplasm Metastasis</subject><subject>Oncogene Proteins, Fusion - antagonists & inhibitors</subject><subject>Oncogene Proteins, Fusion - metabolism</subject><subject>Piperidines - therapeutic use</subject><subject>Proto-Oncogene Proteins c-ret - antagonists & inhibitors</subject><subject>Proto-Oncogene Proteins c-ret - metabolism</subject><subject>Quinazolines - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kF1LwzAUhoMobk7vvZJcetOZjyZpLqVMnUw3dH7chTRNXaRLtUkF_72dm8KBA4fnfTk8AJxiNMYEoYvbfD4mCNMxQ_1gvgeGmBGRCMHYPhgiQUmCM_o6AEchvCOE04yyQzAgjHLOJR6CdlJV1kTYVDCuLHyYLOHUr1zhYtPCZ-1LG7V3BXQearjQ0Vkf4YuLq1_0qguu8cmiCS66LwvvejrEnjLwvr8_rnVdJ7mtazjr_BvMtTe2PQYHla6DPdntEXi6mizzm2Q2v57ml7PEECljYiosRJrSIuWWlDJjmmlRFhJLyYixsiy1LI0oTIXSKsWaGMKJoZhJnmWcUzoC59vej7b57GyIau2C6Z_R3jZdUFhkElGSctSjaIuatgmhtZX6aN1at98KI7UxrXrTamNaMaQ2pvvI2a69K9a2_A_8qaU_MGF4QQ</recordid><startdate>20160520</startdate><enddate>20160520</enddate><creator>Falchook, Gerald S</creator><creator>Ordóñez, Nelson G</creator><creator>Bastida, Christel C</creator><creator>Stephens, Philip J</creator><creator>Miller, Vincent A</creator><creator>Gaido, Lindsay</creator><creator>Jackson, Tiffiny</creator><creator>Karp, Daniel D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160520</creationdate><title>Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer</title><author>Falchook, Gerald S ; Ordóñez, Nelson G ; Bastida, Christel C ; Stephens, Philip J ; Miller, Vincent A ; Gaido, Lindsay ; Jackson, Tiffiny ; Karp, Daniel D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c299t-cf177443b46e2d985a5a7db919952ce9dda9dc7bcf04f41a2c262c31596886633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Cytoskeletal Proteins - antagonists & inhibitors</topic><topic>Cytoskeletal Proteins - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - pathology</topic><topic>Neoplasm Metastasis</topic><topic>Oncogene Proteins, Fusion - antagonists & inhibitors</topic><topic>Oncogene Proteins, Fusion - metabolism</topic><topic>Piperidines - therapeutic use</topic><topic>Proto-Oncogene Proteins c-ret - antagonists & inhibitors</topic><topic>Proto-Oncogene Proteins c-ret - metabolism</topic><topic>Quinazolines - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Falchook, Gerald S</creatorcontrib><creatorcontrib>Ordóñez, Nelson G</creatorcontrib><creatorcontrib>Bastida, Christel C</creatorcontrib><creatorcontrib>Stephens, Philip J</creatorcontrib><creatorcontrib>Miller, Vincent A</creatorcontrib><creatorcontrib>Gaido, Lindsay</creatorcontrib><creatorcontrib>Jackson, Tiffiny</creatorcontrib><creatorcontrib>Karp, Daniel D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Falchook, Gerald S</au><au>Ordóñez, Nelson G</au><au>Bastida, Christel C</au><au>Stephens, Philip J</au><au>Miller, Vincent A</au><au>Gaido, Lindsay</au><au>Jackson, Tiffiny</au><au>Karp, Daniel D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2016-05-20</date><risdate>2016</risdate><volume>34</volume><issue>15</issue><spage>e141</spage><epage>e144</epage><pages>e141-e144</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><cop>United States</cop><pmid>25366691</pmid><doi>10.1200/JCO.2013.50.5016</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2016-05, Vol.34 (15), p.e141-e144 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1789032460 |
| source | MEDLINE; American Society of Clinical Oncology Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Cytoskeletal Proteins - antagonists & inhibitors Cytoskeletal Proteins - metabolism Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - pathology Neoplasm Metastasis Oncogene Proteins, Fusion - antagonists & inhibitors Oncogene Proteins, Fusion - metabolism Piperidines - therapeutic use Proto-Oncogene Proteins c-ret - antagonists & inhibitors Proto-Oncogene Proteins c-ret - metabolism Quinazolines - therapeutic use Treatment Outcome |
| title | Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A01%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20the%20RET%20Inhibitor%20Vandetanib%20in%20a%20Patient%20With%20RET%20Fusion-Positive%20Metastatic%20Non-Small-Cell%20Lung%20Cancer&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Falchook,%20Gerald%20S&rft.date=2016-05-20&rft.volume=34&rft.issue=15&rft.spage=e141&rft.epage=e144&rft.pages=e141-e144&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2013.50.5016&rft_dat=%3Cproquest_cross%3E1789032460%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1789032460&rft_id=info:pmid/25366691&rfr_iscdi=true |